Insulin pumps provides a flexibility in an attempt to mimic physiologic insulin delivery, infusing rapid acting insulin subcutaneously at preselected basal rates to cover a 24 h period in addition to insulin boluses at mealtimes or to correct hyperglycemia that are activated on demand by the patient (20). The gene discussed is INS; the disease is Hyperglycemia.